tiprankstipranks
Advertisement
Advertisement

Twist Bioscience Expands Invenra Stake Through Equity Transactions

Story Highlights
  • On February 11, 2026, Twist Bioscience agreed to issue shares and cash to Invenra for technology and licenses.
  • Twist also acquired about 6% of Invenra and secured board representation, supported by resale registration rights agreements.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Twist Bioscience Expands Invenra Stake Through Equity Transactions

Claim 30% Off TipRanks

Twist Bioscience ( (TWST) ) has issued an update.

On February 11, 2026, Twist Bioscience Corporation agreed to issue up to 632,328 shares of common stock as part of a series of transactions with Invenra Inc. and two of its investors, including up to 324,558 shares and $5 million in cash to Invenra for a license agreement and transfer of certain technology. Twist also committed to issue up to 307,770 shares to two Invenra investors in exchange for preferred stock representing about a 6% stake in Invenra and obtained the right to designate one director to Invenra’s board, while entering related registration rights arrangements to facilitate potential resale of the newly issued shares, strengthening its strategic position and governance influence in Invenra.

The most recent analyst rating on (TWST) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Twist Bioscience stock, see the TWST Stock Forecast page.

Spark’s Take on TWST Stock

According to Spark, TipRanks’ AI Analyst, TWST is a Neutral.

The score is held back primarily by weak cash-flow fundamentals and ongoing losses despite improving margins, while technical momentum and a constructive earnings outlook (raised/reiterated FY2026 growth and breakeven path) provide support; valuation remains challenged given negative earnings and no dividend support.

To see Spark’s full report on TWST stock, click here.

More about Twist Bioscience

Twist Bioscience Corporation operates in the biotechnology industry, focusing on synthetic DNA products and related technologies that support drug discovery and other life science applications. The company uses its DNA synthesis platform to partner with other biotech firms and investors, expanding its technological capabilities and equity interests in complementary businesses.

Average Trading Volume: 1,390,943

Technical Sentiment Signal: Buy

Current Market Cap: $3.01B

For detailed information about TWST stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1